Principles for targeting eicosanoids in the treatment of asthma and allergic diseases
Principles for targeting eicosanoids in the treatment of asthma and allergic diseases
Eicosanoids are a family of fatty acid metabolites that includes prostaglandins, leukotrienes and pro-resolving mediators such as lipoxins and newly-discovered maresins and protectins. Eicosanoids and enzymes involved in their metabolism have been long implicated in the pathogenesis of allergy and asthma but not well understood. Moreover, drugs targeting eicosanoids have been widely used for more than a century but our understanding of their activities and response prediction in asthma and allergic diseases is challenged by the complex nature of eicosanoid biology. Hence, in the era of –omics revolution and redefining and uncovering endotypes and theratypes of asthma and allergic diseases, it is important to identify current research needs and opportunities regarding eicosanoid pathway. In this task force, we aim to conduct a comprehensive state of the art review on the role of eicosanoids in the pathogenesis of allergies and asthma and their potential as targets for prevention and therapy of allergic diseases. In the context of the current COVID-19 pandemics, we are focusing also on the role of lipid mediators in the crosstalk between allergic and viral inflammation.
Chair: Grzegorz Woszczek
Secretary: Milena Sokolowska